tbuckley/cabot-search huggingface dataset:
Abstract B92: Identifying different functional mechanisms of invasion from mesenchymal and proneural subtypes of glioblastoma
Authors: Sungwon Jung, Seungchan Kim, Jeff Kiefer, Michael E. Berens
Journal: Cancer Research (2013)

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR12) of the Conference Proceedings. Citation Format: Sungwon Jung, Seungchan Kim, Jeff Kiefer, Michael E. Berens. Identifying different functional mechanisms of invasion from mesenchymal and proneural subtypes of glioblastoma. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Invasion and Metastasis; Jan 20-23, 2013; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2013;73(3 Suppl):Abstract nr B92.
Risk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections
Authors: T. A. Peterman
Journal: JAMA (1988)

The risk of human immunodeficiency virus (HIV) transmission was studied by interviewing and testing the serum of heterosexual contacts and casual family contacts of adults with transfusion-associated HIV infections. Two (8%) of 25 husbands and ten (18%) of 55 wives who had had sexual contact with infected spouses were seropositive for HIV. Compared with seronegative wives, the seropositive wives were older (median ages, 54 and 62 years;<i>P</i>=.08) and actually reported somewhat fewer sexual contacts with their infected husbands (means, 156 and 82;<i>P</i>&gt;.1). There was no difference in the types of sexual contact or methods of contraception of the seropositive and seronegative spouses. There was no evidence of HIV transmission to the 63 other family members. Although most husbands and wives remained uninfected despite repeated sexual contact without protection, some acquired infection after only a few contacts. This is consistent with an as yet unexplained biologic variation in transmissibility or susceptibility. (<i>JAMA</i>1988;259:55-58)
Cause of Death.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
American Public Wasting Millions on 'Vitamania'
Journal: JAMA (1960)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TOOTH ENAMEL, DENTIN AND CARIES
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ABSTRACTS.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Thallium Poisoning
Authors: Solomon Garb
Journal: JAMA (1965)

<h3>To the Editor:—</h3> The report on thallium poisoning by Dr. Kingery (Cutaneous Medicine,<i>JAMA</i><b>189</b>: 849 [Sept 14] 1964) states that no effective treatment is known. My colleagues at the University of Missouri School of Veterinary Medicine indicate that in the veterinary literature an effective antidote is described, diphenylthiocarbazone. Dr. Lloyd Davis, who is in charge of pharmacology at the veterinary school, has informed me that he has personally observed that diphenylthiocarbazone is a life-saving antidote to thallium in dogs. It is far more effective than general supportive therapy. Accordingly, I would recommend a trial of diphenylthiocarbazone therapy in severe thallium poisoning in man.
Consensus conference. Health applications of smokeless tobacco use
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
^125I Therapy
Authors: E.C. ABBOTT
Journal: Annals of Internal Medicine (1977)

Letters and Corrections1 December 1977125I TherapyE.C. ABBOTT, M.D., R. MARTIN, M.D.E.C. ABBOTT, M.D.Search for more papers by this author, R. MARTIN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-87-6-797_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: We wish to comment on the paper by McDougall and Greig pertaining to125I therapy for Graves' disease (1). This group had previously reported on 257 patients (2). Three other groups have also studied a total of 189 patients, with varying follow-up periods (3-5). We recently reported our experience with125I in 20 cases of Graves' disease and compared the short-term follow-up with that of a similar group given131I between 1972-75 (6). Twenty patients (10 women) were given 32 treatments with125I (mean dose, 5.9 mCi; range, 3 to 8 mCi) based only on clinical severity...References1. MCDOUGALLGREIG IW: 125I Therapy in Graves' disease. Long-term results in 355 patients. Ann Intern Med 85:720-723, 1976 LinkGoogle Scholar2. BREMNERSPENCERRATCLIFFEGREIGRATCLIFFE WCWWJ: The assessment of 125I treatment of thyrotoxicosis. Clin Endocrinol (Oxf) 5:225-234, 1976 CrossrefMedlineGoogle Scholar3. LEWITUSLUBINRECHNICBEN-PORATHFEIGE ZEJMY: Treatment of thyrotoxicosis with 125I and 131I. Semin Nucl Med 1:411-421, 1971 CrossrefMedlineGoogle Scholar4. WEIDINGERJOHNSONWERNER PPS: Five years' experience with iodine-125 therapy of Graves' disease. Lancet 2:74-77, 1974 CrossrefMedlineGoogle Scholar5. SIEMSENWALLACKMARTINNICOLOFF JMRJ: Early results of 125I therapy of thyrotoxic Graves' disease. J Nucl Med 15:257-260, 1974 MedlineGoogle Scholar6. ABBOTTSCHLOSSBERGMARTINHICKEY EARJ: Short-term outcome of I131 and I125 therapy in Graves' disease (abstract). Ann R Coll Physicians Surg Can 10:48, 1977 Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: E.C. ABBOTT, M.D.; R. MARTIN, M.D. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 December 1977Volume 87, Issue 6Page: 797-797 ePublished: 1 December 2008 Issue Published: 1 December 1977 PDF downloadLoading ...
P294 Benefits of tiotropium/olodaterol over tiotropium at delaying clinically significant events in patients with copd classified as gold b
Journal: Thorax (2016)

AbstractR Buhl reports financial support to his institution from Boehringer Ingelheim during the conduct of the study and, outside of the submitted work, financial support from Boehringer Ingelheim, AstraZeneca, Chiesi, Novartis, Teva, Roche and GlaxoSmithKline for attendance at advisory boards and speaking activities, and research support to his institution from Boehringer Ingelheim, GlaxoSmithKline, Novartis and Roche.L McGarvey reports personal fees from Applied Clinical Intelligence during the conduct of the study, and grants from Asthma UK, NI Chest Heart & Stroke, NC3Rs, British Heart Foundation and Chiesi, and other from Boehringer Ingelheim, GlaxoSmithKline, Chiesi, Almirall and NAPP outside the submitted work.S Korn has received grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis and Takeda, grants from Teva and MedImmune, and personal fees from Almirall and Grifols.GT Ferguson, during the conduct of the study, reports grants, personal fees and non-financial support from Boehringer Ingelheim and, outside the submitted work, grants, personal fees and non-financial support from Boehringer Ingelheim, personal fees from GlaxoSmithKline, grants and personal fees from Novartis, AstraZeneca, Pearl Therapeutics and Sunovion, and grants from Forest.L Grönke, C Hallmann and F Voß are employees of Boehringer Ingelheim Pharma GmbH & Co. KG.KF Rabe reports financial for support for consultancy work from AstraZeneca, Chiesi, Novartis, MSD and GlaxoSmithKline, and grants from Altana, Novartis, AstraZeneca, MSD and Nycomed.F Maltais reports financial support from Boehringer Ingelheim during the conduct of the study and, outside of the submitted work, financial support from Boehringer Ingelheim and GlaxoSmithKline for attendance at advisory boards, financial support from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca and Novartis for speaking activities, and research support from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Nycomed and Novartis.
F2-isoprostane excretion in human bile of patients with biliary tract and pancreatic disorders . Section of Liver Disease &amp; Nutr., Alcohol Research Ctr., Bronx VA and Beth Israel (North Division) Medical Centers and Mount Sinai School of Medicine, NY, NY
Journal: Hepatology (1995)

Primary energy requirements have close interaction with resource, technology, environment, infrastructure, as well as the socio-economic development. This study links the entire supply chain of the Chinese economy from energy extraction to final consumption by using input-output analysis and structural path analysis. The results show that the domestic primary energy input amounted to 3318.7 Mtce in 2012, of which 49.5% was induced by investment demands. Despite being one of the world's largest energy importers, embodied energy uses (EEUs) in China’s exports were equivalent to about one fourth of its total domestic supply. All Manufacturing sectors accounted for 44.3% of the total EEUs, followed by Construction for 33.3%, Services for 11.6% and Power & Heat for 3.9%. After examining the embodied energy paths, critical economic sectors such as Construction of Buildings, Construction Installation Activities, Transport Via Road, Production and Supply of Electricity and Steam and Processing of Steel Rolling Processing, and supply chain routes starting from final uses to resource extraction such as “Capital formation → Construction of Buildings → Production and Supply of Electricity and Steam → Production and Supply of Electricity and Steam → Mining and Washing of Coal”, were identified as the main contributors to China’s raw coal and other primary energy requirements. Restructuring Chinese economy from manufacturing industries to construction and services with huge economic costs cannot fundamentally conserve energy, owing to their almost identical structures in higher production tiers; more appropriate policies on technology efficiency gains, energy mix improvement, economic structure adjustment and green consumption deserve to be considered in the light of upstream and downstream responsibilities from a systematic viewpoint.
Pheochromocytoma in multiple endocrine adenomatosis. Efficacy of computer tomography
Authors: J. L. Thomas
Journal: JAMA (1981)

PHEOCHROMOCYTOMA is an integral part of the multiple endocrine adenomatosis type II (MEA II) and has been reported in patients with multiple endocrine adenomatosis type I (MEA I).<sup>1</sup>The clinical diagnosis of pheochromocytoma may not be suspected in these patients, since they are often normotensive and may have normal biochemical study results.<sup>2,3</sup>Yet the detection of pheochromocytoma in patients with MEA syndromes is important, since surgery for associated tumors may precipitate hypertensive crises.<sup>3</sup>Computed tomography (CT) is an imaging modality that can noninvasively detect adrenal tumors with a high degree of accuracy.<sup>4</sup>The purpose of this communication is to discuss the role of CT in the detection of pheochromocytoma in patients with MEA syndromes. <h3>Report of Cases</h3><h3>Case 1.—</h3> A 38-year-old woman with a 17-year history of metastatic medullary thyroid carcinoma complained of a recent onset of pulsatile headaches. These episodes lasted two to three minutes
Abstract 16028: Contrast Enhancement Dynamics of Radiofrequency Ablation Lesions
Authors: Lee Linstroth, Nathan A Angel, Eugene Kholmovski, Rob Macleod, Josh Silvernagel, Nassir Marrouche, Ravi Ranjan
Journal: Circulation (2015)

Introduction: Late gadolinium enhanced MRI (LGE-MRI) done acutely after ablation shows a central area of no-reflow that enhances slowly. The dynamics and predictive value of this region to chronic lesion volume is unknown. Methods: RF lesions were created in a canine ventricle model using a 4 mm irrigated tip catheter. 3D LGE-MRI images were acquired in a 3T (Verio, Siemens) MR scanner (1.25 x 1.25 x 2.5 mm 3 ) at weeks 0, 1, 2, and 4 post ablation at multiple time points after contrast injection (Multihance, 0.15 mmol/Kg). The central no-flow volumes in MRI were normalized to the histological volumes and this ratio was compared across multiple post-contrast injection times. Results: The number of lesions analyzed was 33, 27, 11 and 20 at week 0, 1, 2 and 4, respectively in four animals. Histological volumes had a mean of 99±52 mm 3 (range 32-220 mm 3 ). The initial MRI done within five mins of contrast injection had average no reflow volumes of 330±170 mm 3 for week 0, 270±170 mm 3 at week 1, 120±100 mm 3 at week 2, and 50±46 mm 3 at week 4. The normalized no reflow volumes (normalized to chronic histological volume) for the initial MRI was 4.28±1.44 at week 0, 3.40±1.15 at week 1, 1.94±0.68 at week 2, and 0.65±0.42 at week 4. Based on a logarithmic fit to the decay in volume, the no reflow volume equaled the final histological volume 26.6 mins after contrast injection on day 0, 30.9 mins on week 1, 8.2 mins on week 2 and 0.3 mins after week 4. By one month after ablation, the no-reflow was negligible and the final lesion completely enhanced immediately after contrast injection. Conclusions: The no-reflow volume declines exponentially acutely after ablation and results in an accurate assessment of final lesion volume 26 to 30 minutes after contrast injection up to one week post - ablation. With tissue remodeling, the no reflow area enhances faster such that one month after ablation, lesions enhance completely immediately following contrast injection.
Identification of Platform-Independent Gene Expression Markers of Cisplatin Nephrotoxicity
Authors: Karol L. Thompson, Cynthia A. Afshari, Rupesh P. Amin, Timothy A. Bertram, Bruce Car, Michael Cunningham, Clive Kind, Jeffrey A. Kramer, Michael Lawton, Michael Mirsky, Jorge M. Naciff, Victor Oreffo, P. Scott Pine, Frank D. Sistare
Journal: Environmental Health Perspectives (2004)

Within the International Life Sciences Institute Committee on Genomics, a working group was formed to focus on the application of microarray technology to preclinical assessments of druginduced nephrotoxicity.As part of this effort, Sprague-Dawley rats were treated with the nephrotoxicant cisplatin at doses of 0.3-5 mg/kg over a 4-to 144-hr time course.RNA prepared from these animals was run on a variety of microarray formats at multiple sites.A set of 93 differentially expressed genes associated with cisplatin-induced renal injury was identified on the National Institute of Environmental Health Sciences (NIEHS) custom cDNA microarray platform using quadruplicate measurements of pooled animal RNA.The reproducibility of this profile of statistically significant gene changes on other platforms, in pooled and individual animal replicate samples, and in an independent study was investigated.A good correlation in response between platforms was found among the 48 genes in the NIEHS data set that could be matched to probes on the Affymetrix RGU34A array by UniGene identifier or sequence alignment.Similar results were obtained with genes that could be linked between the NIEHS and Incyte or PHASE-1 arrays.The degree of renal damage induced by cisplatin in individual animals was commensurate with the number of differentially expressed genes in this data set.These results suggest that gene profiles linked to specific types of tissue injury or mechanisms of toxicity and identified in wellperformed replicated microarray experiments may be extrapolatable across platform technologies, laboratories, and in-life studies.
A Program To Prevent Bleeding Complications in Older Patients Taking Warfarin
Journal: Annals of Internal Medicine (2000)

Summaries for Patients7 November 2000A Program To Prevent Bleeding Complications in Older Patients Taking WarfarinSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-9-200011070-00005 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Warfarin (sold under the brand name Coumadin) is a medicine that interferes with blood clotting. Warfarin can prevent some conditions that result from blood clots, such as stroke, pulmonary emboli (blood clots in the lung), and deep venous thrombosis (blood clots in the legs). People taking warfarin need careful monitoring with blood tests to be sure that the dose being given reduces the blood's ability to clot enough to prevent clots from forming, but not so much that bleeding occurs spontaneously. Serious bleeding (for example, into the digestive ... Author, Article, and Disclosure InformationThe summary below is from the full report titled “A Multicomponent Intervention To Prevent Major Bleeding Complications in Older Patients Receiving Warfarin. A Randomized, Controlled Trial.” It is in the 7 November 2000 issue of Annals of Internal Medicine (volume 133, pages 687-695). The authors are RJ Beyth, L Quinn, and CS Landefeld.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoA Multicomponent Intervention To Prevent Major Bleeding Complications in Older Patients Receiving Warfarin Rebecca J. Beyth , Linda Quinn , and C. Seth Landefeld Metrics 7 November 2000Volume 133, Issue 9 Page: I-7 Keywords Brain Deep vein thrombosis Gastrointestinal tract Hematologic tests Hemorrhage Hospitalizations Lungs Patients Stroke Thrombosis ePublished: 7 November 2000 Issue Published: 7 November 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...